Tags

Type your tag names separated by a space and hit enter

The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.
J Neurol. 2006 Feb; 253(2):171-5.JN

Abstract

OBJECTIVES

We studied the effect of quetiapine in drug induced psychosis (DIP) in Parkinson's disease (PD) patients with dementia (PDDEM) and without dementia (PDNODEM) in a 6-month open study.

METHODS

Thirty five consecutive PD patients with DIP (19 of them demented [DSMIV criteria]) were examined. Assessment included Mini-Mental State Examination (MMSE), UPDRS (motor part), Brief Psychiatric Rating Scale (BPRS), Clinical Global Improvement Scale (CGIS) and Hamilton test (for depression). Quetiapine was administered in a flexible dose 25-600 mg daily. Out of the 35 patients included in the study, 24 completed treatment with quetiapine (14 demented and 10 without dementia). Treatment was stopped in 11 patients (5 demented).

RESULTS

Intention to treat patient (ITT) analysis did not show a significant quetiapine effect (BPRS), although in about 30% a good outcome was reported by the family (CGIS). Among the patients who completed the study (n = 24), in the PDNODEM group (n = 10) BPRS improved almost significantly (p = 0.06) while in the PDDEM group the BPRS did not change. According to the CGIS, a good improvement was observed in 50% of the PDDEM group (7/14) and 40% of the PDNODEM group (4/10). Motor features of PD patients worsened mildly (p = 0.05) in the PDDEM group.

CONCLUSION

In this open trial, quetiapine was not beneficial in the ITT group using the BPRS, although families reported improvement in about 30% of patients (CGIS). Among patients who completed the study, quetiapine was more effective in the PDNODEM group. A double blind study with quetiapine is required.

Authors+Show Affiliations

Assaf Harofeh Medical Center, Zerifin, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

16096815

Citation

Prohorov, T, et al. "The Effect of Quetiapine in Psychotic Parkinsonian Patients With and Without Dementia. an Open-labeled Study Utilizing a Structured Interview." Journal of Neurology, vol. 253, no. 2, 2006, pp. 171-5.
Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006;253(2):171-5.
Prohorov, T., Klein, C., Miniovitz, A., Dobronevsky, E., & Rabey, J. M. (2006). The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. Journal of Neurology, 253(2), 171-5.
Prohorov T, et al. The Effect of Quetiapine in Psychotic Parkinsonian Patients With and Without Dementia. an Open-labeled Study Utilizing a Structured Interview. J Neurol. 2006;253(2):171-5. PubMed PMID: 16096815.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. AU - Prohorov,T, AU - Klein,C, AU - Miniovitz,A, AU - Dobronevsky,E, AU - Rabey,J M, Y1 - 2005/08/17/ PY - 2004/12/05/received PY - 2005/05/17/accepted PY - 2005/05/10/revised PY - 2005/8/13/pubmed PY - 2006/6/29/medline PY - 2005/8/13/entrez SP - 171 EP - 5 JF - Journal of neurology JO - J Neurol VL - 253 IS - 2 N2 - OBJECTIVES: We studied the effect of quetiapine in drug induced psychosis (DIP) in Parkinson's disease (PD) patients with dementia (PDDEM) and without dementia (PDNODEM) in a 6-month open study. METHODS: Thirty five consecutive PD patients with DIP (19 of them demented [DSMIV criteria]) were examined. Assessment included Mini-Mental State Examination (MMSE), UPDRS (motor part), Brief Psychiatric Rating Scale (BPRS), Clinical Global Improvement Scale (CGIS) and Hamilton test (for depression). Quetiapine was administered in a flexible dose 25-600 mg daily. Out of the 35 patients included in the study, 24 completed treatment with quetiapine (14 demented and 10 without dementia). Treatment was stopped in 11 patients (5 demented). RESULTS: Intention to treat patient (ITT) analysis did not show a significant quetiapine effect (BPRS), although in about 30% a good outcome was reported by the family (CGIS). Among the patients who completed the study (n = 24), in the PDNODEM group (n = 10) BPRS improved almost significantly (p = 0.06) while in the PDDEM group the BPRS did not change. According to the CGIS, a good improvement was observed in 50% of the PDDEM group (7/14) and 40% of the PDNODEM group (4/10). Motor features of PD patients worsened mildly (p = 0.05) in the PDDEM group. CONCLUSION: In this open trial, quetiapine was not beneficial in the ITT group using the BPRS, although families reported improvement in about 30% of patients (CGIS). Among patients who completed the study, quetiapine was more effective in the PDNODEM group. A double blind study with quetiapine is required. SN - 0340-5354 UR - https://www.unboundmedicine.com/medline/citation/16096815/The_effect_of_quetiapine_in_psychotic_Parkinsonian_patients_with_and_without_dementia__An_open_labeled_study_utilizing_a_structured_interview_ L2 - https://dx.doi.org/10.1007/s00415-005-0943-4 DB - PRIME DP - Unbound Medicine ER -